Literature DB >> 30298350

Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension.

Chenggui Miao1, Jun Chang2, Guoxue Zhang3.   

Abstract

Hypertension is the most widespread disease in the world affecting humans and imparts a significant cardiovascular and renal risk to patients, and extensive research over the past few decades has enhanced our understanding of the underlying pathogenesis of hypertension. A growing number of studies have shown that miRNAs are involved in the pathological mechanisms of hypertension. This review summarizes the current understanding of miRNA-mediated modulation of gene expression in the hypertension pathogenesis in the past few years. A systematic review of PUBMED, EMBASE and SCOPUS was conducted for studies published in the past few years. The review covers three topics: miRNAs in pulmonary arterial hypertension (PAH), miRNAs and systemic arterial hypertension (SAH), miRNAs and application in hypertension. This review summarizes the current understanding of miRNA-mediated modulation in the hypertension pathogenesis in the past few years, with especially emphasis on miRNAs in PAH. We also discussed the roles of miRNAs in SAH, and the therapeutic applications of these miRNAs will be detailed discussed in this review. Evidence suggests that miRNAs are involved in the pathological mechanisms of hypertension, and the roles of miRNAs in the hypertension pathogenesis are confirmed. We need to further investigate the regulated roles of miRNAs in the pathogenesis of hypertension and the application of miRNAs in the diagnosis and treatment of this disease in the future.

Entities:  

Keywords:  Hypertension; Pulmonary arterial hypertension; Systemic arterial hypertension; Therapeutic application; microRNA

Mesh:

Substances:

Year:  2018        PMID: 30298350     DOI: 10.1007/s11033-018-4335-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  88 in total

1.  Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.

Authors:  Jared M McLendon; Sachindra R Joshi; Jeff Sparks; Majed Matar; Jason G Fewell; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry; William T Gerthoffer
Journal:  J Control Release       Date:  2015-05-13       Impact factor: 9.776

2.  Role of miR206 in genistein-induced rescue of pulmonary hypertension in monocrotaline model.

Authors:  Salil Sharma; Soban Umar; Alexander Centala; Mansoureh Eghbali
Journal:  J Appl Physiol (1985)       Date:  2015-10-15

Review 3.  Trends in Coronary Heart Disease Epidemiology in India.

Authors:  Rajeev Gupta; Indu Mohan; Jagat Narula
Journal:  Ann Glob Health       Date:  2016 Mar-Apr       Impact factor: 2.462

4.  MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension.

Authors:  Alexander M K Rothman; Nadine D Arnold; Josephine A Pickworth; James Iremonger; Loredana Ciuclan; Robert M H Allen; Sabine Guth-Gundel; Mark Southwood; Nicholas W Morrell; Matthew Thomas; Sheila E Francis; David J Rowlands; Allan Lawrie
Journal:  J Clin Invest       Date:  2016-05-23       Impact factor: 14.808

5.  MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β.

Authors:  Bi Deng; Jie Du; Rong Hu; Ai-Ping Wang; Wei-Hua Wu; Chang-Ping Hu; Yuan-Jian Li; Xiao-Hui Li
Journal:  Life Sci       Date:  2016-01-29       Impact factor: 5.037

6.  Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension: possible relevance of miR-23a.

Authors:  Irene Sarrion; Lara Milian; G Juan; Mercedes Ramon; Idelfonso Furest; Carmen Carda; Julio Cortijo Gimeno; Manuel Mata Roig
Journal:  Oxid Med Cell Longev       Date:  2015-02-25       Impact factor: 6.543

7.  Circulating mircoRNA-21 as a predictor for vascular restenosis after interventional therapy in patients with lower extremity arterial occlusive disease.

Authors:  Bo Zhang; Ye Yao; Qing-Feng Sun; Si-Qi Liu; Bao Jing; Chao Yuan; Xin-Yu Liu; Tong Jiao; Hao-Cheng Li; Hai-Yang Wang
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

8.  MicroRNA-143 Activation Regulates Smooth Muscle and Endothelial Cell Crosstalk in Pulmonary Arterial Hypertension.

Authors:  Lin Deng; Francisco J Blanco; Hannah Stevens; Ruifang Lu; Axelle Caudrillier; Martin McBride; John D McClure; Jenny Grant; Matthew Thomas; Maria Frid; Kurt Stenmark; Kevin White; Anita G Seto; Nicholas W Morrell; Angela C Bradshaw; Margaret R MacLean; Andrew H Baker
Journal:  Circ Res       Date:  2015-08-26       Impact factor: 17.367

9.  MEF2C-MYOCD and Leiomodin1 Suppression by miRNA-214 Promotes Smooth Muscle Cell Phenotype Switching in Pulmonary Arterial Hypertension.

Authors:  Sanghamitra Sahoo; Daniel N Meijles; Imad Al Ghouleh; Manuj Tandon; Eugenia Cifuentes-Pagano; John Sembrat; Mauricio Rojas; Elena Goncharova; Patrick J Pagano
Journal:  PLoS One       Date:  2016-05-04       Impact factor: 3.240

10.  Upregulation of MicroRNA-214 Contributes to the Development of Vascular Remodeling in Hypoxia-induced Pulmonary Hypertension Via Targeting CCNL2.

Authors:  HaiTao Liu; Yin Tao; Mai Chen; Jin Yu; Wei-Jie Li; Ling Tao; Yan Li; Fei Li
Journal:  Sci Rep       Date:  2016-07-06       Impact factor: 4.379

View more
  7 in total

Review 1.  Clinical value of non-coding RNAs in cardiovascular, pulmonary, and muscle diseases.

Authors:  Sébastien Bonnet; Olivier Boucherat; Roxane Paulin; Danchen Wu; Charles C T Hindmarch; Stephen L Archer; Rui Song; Joseph B Moore; Steeve Provencher; Lubo Zhang; Shizuka Uchida
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-04       Impact factor: 4.249

2.  Circular RNA: a new biomarker for different types of hypertension.

Authors:  Durairaj Sekar
Journal:  Hypertens Res       Date:  2019-07-17       Impact factor: 3.872

Review 3.  The Biological Bases of Group 2 Pulmonary Hypertension.

Authors:  Ana I Fernández; Raquel Yotti; Ana González-Mansilla; Teresa Mombiela; Enrique Gutiérrez-Ibanes; Candelas Pérez Del Villar; Paula Navas-Tejedor; Christian Chazo; Pablo Martínez-Legazpi; Francisco Fernández-Avilés; Javier Bermejo
Journal:  Int J Mol Sci       Date:  2019-11-23       Impact factor: 5.923

4.  Upregulation of miR-361-3p suppresses serotonin-induced proliferation in human pulmonary artery smooth muscle cells by targeting SERT.

Authors:  Ying Zhang; Yongbin Chen; Guo Chen; Yingling Zhou; Hua Yao; Hong Tan
Journal:  Cell Mol Biol Lett       Date:  2020-10-07       Impact factor: 5.787

5.  Circulating Microparticles Are Differentially Increased in Lowlanders and Highlanders with High Altitude Induced Pulmonary Hypertension during the Cold Season.

Authors:  Akylbek Sydykov; Aleksandar Petrovic; Abdirashit M Maripov; Marija Gredic; Daniel Gerd Bermes; Nadira Kushubakova; Kubatbek Muratali Uulu; Christina Pilz; Meerim Cholponbaeva; Melis Duishobaev; Samatbek Satybaldyev; Nurgul Satieva; Argen Mamazhakypov; Meerim Sartmyrzaeva; Nazgul Omurzakova; Zhainagul Kerimbekova; Nursultan Baktybek; Cholpon Kulchoroeva; Oleg Pak; Lan Zhao; Norbert Weissmann; Sergey Avdeev; Leonid N Maslov; Hossein Ardeschir Ghofrani; Ralph Theo Schermuly; Akpay S Sarybaev; Djuro Kosanovic
Journal:  Cells       Date:  2022-09-20       Impact factor: 7.666

6.  MircoRNA in Extracellular Vesicles from Patients with Pulmonary Arterial Hypertension Alters Endothelial Angiogenic Response.

Authors:  Avinash Khandagale; Padraic Corcoran; Maryam Nikpour; Anders Isaksson; Gerhard Wikström; Agneta Siegbahn; Christina Christersson
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

7.  Blood microRNA 202-3p associates with the risk of essential hypertension by targeting soluble ST2.

Authors:  Lu Li; Danrong Zhong; Yudan Xie; Xinlei Yang; Zuozhong Yu; Dangui Zhang; Xinghua Jiang; Yanqing Wu; Fangqin Wu
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.